New research from the University of Virginia School of Medicine and collaborators shows that microorganisms found in our guts can worsen dangerous Clostridioides difficile infections, a discovery that could help doctors identify patients at risk for severe illness and open the door to new treatments.
C. difficile is a bacterium that can cause potentially deadly infections, particularly among the elderly and people on long-term antibiotics. These infections are characterized by diarrhea, nausea and fever.
“C. diff,” as it is commonly known, strikes more than 350,000 Americans a year. Once infected, patients are prone to suffer re-infections. Among those who survive, one in six will develop another case within eight weeks, according to the federal Centers for Disease Control and Prevention. As such, C. diff can be a major problem for hospitals and nursing facilities.
UVA’s new findings help explain why certain patients are at particular risk. The researchers determined that a group of antibiotic-resistant “opportunistic pathogens” found in the gut called enterococci can make C. diff more potent and dangerous.
“The interactions between C. diff, other microbes and the human gut are highly complex. This study leveraged expertise from a large, multidisciplinary team across several institutions to disentangle these complex interactions and discover key mechanisms that help C. diff cause disease,” said researcher Jason Papin of UVA’s Department of Biomedical Engineering, a joint program of the School of Medicine and School of Engineering.
“With this greater understanding, we have an opportunity to develop new therapeutic strategies to treat this dangerous infection,” Papin said.
Jason Papin, a professor in UVA’s biomedical engineering program, examined the interactions between C. diff and other microbes. (UVA Engineering photo)
Enterococci are bacteria that can, on their own, cause dangerous infections that are difficult to treat. For example, they can cause meningitis, urinary tract infections (which can be very serious in the elderly) and the painful gastrointestinal disease diverticulitis, as well as other illnesses. But the researchers found that the threat they pose does not end there.
The research team collected stool samples from patients with C. difficile infections at Vanderbilt University Medical Center, Children’s Hospital of Philadelphia and the Hospital of the University of Pennsylvania. They then used a combination of lab tests and advanced computer modeling to better understand how C. diff interacts with other microorganisms in the gut.
They found that enterococci make for a dangerous ally for C. diff. Enterococci produce amino acids, including leucine and ornithine, which make C. difficile a more potent threat for patients whose gut compositions have been disrupted by antibiotics.
Papin and his team developed powerful computer models that helped the researchers understand and predict the complex changes in the gut. Their work, combined with other labs’ research, showed that enterococci can dramatically reshape the “metabolome” – the collection of metabolites such as amino acids – in the gut.
These changes, the researchers report, ultimately reprogram C. difficile and enhance its disease-causing behaviors.
“The computational modeling that Matthew Jenior [UVA postdoctoral fellow in the Papin lab] performed was instrumental in discovering the role of amino acids in the interaction between C. diff and enterococci,” Papin said. “The computational models that Matthew constructed will continue to help us better understand the molecular processes in C. diff that cause disease.”
By better understanding how C. diff interacts with enterococci and other microorganisms in the gut, doctors will be better positioned to battle this common and serious infection, the researchers say.
“Biology is a data-rich science and the power of computational models to use these data is only in its infancy,” Papin said. “We’re excited about the innumerable opportunities to use data science and computer modeling to drive biological discovery.”
The researchers have published their findings in the prestigious scientific journal Nature. The team consisted of Alexander B. Smith, Matthew L. Jenior, Orlaith Keenan, Jessica L. Hart, Jonathan Specker, Arwa Abbas, Paula C. Rangel, Chao Di, Jamal Green, Katelyn A. Bustin, Jennifer A. Gaddy, Maribeth R. Nicholson, Clare Laut, Brendan J. Kelly, Megan L. Matthews, Daniel R. Evans, Daria Van Tyne, Emma E. Furth, Papin, Frederic D. Bushman, Jessi Erlichman, Robert N. Baldassano, Michael A. Silverman, Gary M. Dunny, Boone M. Prentice, Eric P. Skaar and Joseph P. Zackular.
The research was supported by the National Institutes of Health, grants K22AI7220, R35GM138369, R01AI138581, R01AI145992, R01HD090061, R01AT010253, UL1TR000445, K23 AI121485 and 1DP1DA051620; a Children’s Hospital of Philadelphia Junior Faculty Pilot Grant; a Cell and Molecular Biology Training Grant, T32GM07229; a UVA TransUniversity Microbiome Initiative Pilot Grant; Chemical and Biology Interface Training Grant 5T32GM071339-15; Centers for Disease Control and Prevention grant BAA 200-2016-91937; and Commonwealth Universal Research Enhancement program grant SAP#4100068710.
To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog.
Media Contact
Article Information
April 24, 2024
